Category - Developments

Health Canada has cleared IntelGenx’s (OTCQX:IGXT; TSXV:IGX) clinical trial application for its Montelukast VersaFilm intended for the treatment of mild-to-moderate Alzheimer’s disease (AD). The phase 2a proof-of...

Hutchison China MediTech (AIM, NASDAQ:HCM) has initiated a U.S. Phase 1 bridging clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3...

3D Signatures’ (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) non-brokered private placement has been fully subscribed for and has closed for gross proceeds of $1,622,673. The private placement involved the sale of 8,113,365 units at...

The U.S. Patent and Trademark Office granted a notice of allowance to IntelGenx (OTCQX:IGXT; TSXV:IGX) for a patent entitled, “Device and Method of Treating Conditions Associated with Neuroinflammation.” The...

Vital Therapies (NASDAQ:VTL) has been selected for addition to the NASDAQ biotechnology index, effective prior to the opening on Dec. 18. Companies in the index must meet eligibility requirements, including minimum...

A peer-reviewed article published in the current issue of Biomedical Materials has provided further validation that Ortho Regenerative Technologies’ (CSE:ORTH) Ortho-R hybrid implants release more growth factors and...

Closely-held NeuroproteXeon announced the publication of a second finding from a randomized, controlled Phase 2 trial of inhaled xenon and oxygen, combined with hypothermia, for out-of-hospital cardiac arrest (OHCA)...

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a binding term sheet with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. of Italy, giving Molteni an exclusive license to commercialize Probuphine...

Closely-held Spartan Bioscience has launched the Spartan Legionella Detection System, the first on-site DNA test for Legionella that can detect and quantify Legionella bacteria in 45 minutes. The system consists of a...

The European Medicines Agency has accepted for review Titan Pharmaceuticals’ (NASDAQ:TTNP) marketing authorization application (MAA) for Probuphine. The acceptance marks the beginning of the EMA’s regulatory...